ExpreS2ion Biotech Holding

1,42SEK +1,57 %

HC Andersen Capital saa maksun yhtiöltä ExpreS2ion Biotech Holding DigitalIR/Corporate Visibility -sopimuksesta. Katso vastuuvapauslauseke.

310 sijoittajaa seuraa yhtiötä

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

Lue lisää
5,09 milj.
−2 507,07 %
P/E -luku
Osinkotuotto %
First North Stockholm
Päivän matalin / päivän korkein hinta
1,26 / 1,42 SEK
73 milj. SEK
137,86 t. SEK
Vaihtomäärä, kappaletta
101 t.

Suurimmat omistajat
Lähde: Millistream Market Data AB

Saxo Bank A/S Client Assets7,8 %7,8 %
Sydbank A/S5,5 %5,5 %
Inderes Premium
Premium ei aktivoitu

Tämä sisältö on vain Inderes Premium -käyttäjille.

Life Science Seminar – Wrap up from our event last week – Thursday the 31st. of August.

Life Science Seminar – Wrap up from our event last week – Thursday the 31st. of August.

Analyytikon kommentti05.09.2023 - Henrik Ekman, Claus Thestrup
ExpreS2ion Biotechnologies – Presentation of Q2 interim report 2023

On 17 August, ExpreS2ion Biotechnologies will release its Q2 2023 results. On the same day at 11.30 CEO Bent Frandsen and CFO, Keith Alexander will take a deeper dive into the results and achievements. During the event, it will be possible to ask questions live.

Webcast17.08.2023 - Michael Friis
ExpreS2ion Biotechnologies: Phase 3 Covid-19 topline results meets primary objective

The partner, Bavarian Nordic, has released its phase 3 topline results for the COVID-19 booster vaccine candidate. The booster study successfully met its primary objective.

Analyytikon kommentti27.06.2023 - Michael Friis
ExpreS2ion Biotechnologies: Mixed 12-month data on COVID-19 candidate 

Today, ExpreS2ion Biotechnologies' partner, Bavarian Nordic, released its 12-month durability data in the phase 2 trial for the candidate ABNCoV2.

Analyytikon kommentti16.06.2023 - Michael Friis